Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertriglyceridemia-why, when and how should it be treated?

I Gouni-Berthold1, W Krone

  • 1Department of Internal Medicine II, University of Cologne and Center of Moleclar Medicine Cologne (CMMC), Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany. Wilhelm.krone@uk-koeln.de

Zeitschrift Fur Kardiologie
|November 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Juvenile nasopharyngeal angiofibroma: nationwide study on incidence, diagnosis, treatment, and recurrence.

Rhinology·2026
Same author

[Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations].

Innere Medizin (Heidelberg, Germany)·2023
Same author

Vitamin D supplementation of 4000 IU daily and cardiac function in patients with advanced heart failure: The EVITA trial.

International journal of cardiology·2019
Same author

Vitamin D supplementation and bone turnover in advanced heart failure: the EVITA trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Randomized supplementation of 4000 IU vitamin D<sub>3</sub> daily vs placebo on the prevalence of anemia in advanced heart failure: the EVITA trial.

Nutrition journal·2017
Same author

Abdominal aortic aneurysms: do not underestimate the role of diabetes.

Expert review of cardiovascular therapy·2015
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[On pathogenesis of coronary heart disease].

Zeitschrift fur Kardiologie·2016
Same journal

An overview of the evolution of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis.

Zeitschrift fur Kardiologie·2016
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[Reconstructive surgery of the aortic root].

Zeitschrift fur Kardiologie·2016
See all related articles

High triglyceride levels may be an independent risk factor for cardiovascular disease. Further prospective trials are needed to confirm if lowering triglycerides reduces coronary events and stroke.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • The link between serum triglyceride levels and cardiovascular disease (CVD) remains unclear despite extensive research.
  • Hypertriglyceridemia is often considered an independent risk factor for CVD, yet no specific triglyceride targets exist for prevention.
  • Current lipid-lowering therapies prioritize optimizing low-density lipoprotein (LDL) cholesterol for overall cardiovascular risk reduction.

Purpose of the Study:

  • To review the existing evidence on the relationship between triglyceride levels and cardiovascular disease.
  • To discuss therapeutic strategies for managing hypertriglyceridemia.
  • To highlight the need for prospective trials investigating the clinical impact of triglyceride reduction on cardiovascular outcomes.

Main Methods:

Related Experiment Videos

  • Review of existing epidemiological data and clinical trial analyses.
  • Analysis of post-hoc data from studies like the Helsinki Heart Study, VA-HDL, and BIPS.
  • Synthesis of evidence regarding lifestyle modifications and pharmacological interventions (fibrates, omega-3 fatty acids, niacin).

Main Results:

  • Evidence suggests hypertriglyceridemia may be an independent CVD risk factor.
  • Post-hoc analyses indicate potential benefits of fibrates in treating hypertriglyceridemia, particularly in obese, insulin-resistant individuals.
  • Current guidelines focus on LDL cholesterol reduction, not specific triglyceride targets.

Conclusions:

  • While evidence suggests a link, the precise role of triglycerides in CVD requires further investigation.
  • Therapeutic options for triglyceride lowering include lifestyle changes and medications like fibrates.
  • Prospective trials are essential to determine if reducing triglyceride levels directly impacts clinical endpoints such as coronary events and stroke.